Fundraising Fox
Clearside Biomedical
Alpharetta, US · Founded 2011 · Delaware corporation · 22 employees on LinkedIn · 5 known investors
Find your way into Clearside Biomedical
Each arrow is one introduction. Sign up to fill in the first one.
198 people can intro you to Daniel
Ask Christy Shaffer to introduce you to Daniel H. White
You →Christy · together at Clearside Biomedical →Daniel
15 people can intro you to Glenn
Ask Jamie Chen to introduce you to Glenn Noronha
You →Jamie · together at PYC Therapeutics →Glenn
Sign up to find every way you can get introduced to Clearside Biomedical
- Your email: who you already know at Clearside Biomedical, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Clearside Biomedical team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Clearside Biomedical is an intellectual property holding, investment, and commercialization company focused on its suprachoroidal space (SCS) ocular drug-delivery platform and microinjector technology. Following its emergence from Chapter 11 in 2026, it works to rehabilitate, use, and monetize its retained intellectual property.
Founders & leadership
Clearside Biomedical was founded in 2011 by Mark Prausnitz.
CD
Charles DeignanExecutive
GN
Glenn NoronhaChief Scientific Officer; Head of Development2013–2018Glenn Noronha is an executive officer at Clearside Biomedical with over 20 years of experience in pharmaceutical development across translational, clinical, and preclinical stages. He led the clinical and regulatory development of XIPERE (approved 2021 for macular edema due to uveitis) through NDA, and has contributed to the development of multiple approved therapeutics spanning autoimmune, inflammatory, cardiovascular, and oncology indications.
DH
Daniel H. WhiteFounder and former CEO2011–2019Daniel H. White is an executive officer and director at Clearside Biomedical, an ophthalmic drug-delivery and biotech company where he has led multiple rounds of financing and regulatory milestones including NDA filings.
Board
EZ
Evgeny ZaytsevBoard director
DY
CL
Christy L. Shaffer, Ph.D.Board director
CB
CS
WH
William HumphriesBoard director
GC
Gerald Cagle, Ph.D.Board director
RC
Richard CroarkinBoard director
Investors · 5
Mountain Group Capitallisted by Mountain Group CapitalNashville
How we know: Mountain Group Capital's portfolio page · Not right? Tell us
Hatteras Venture PartnersreportedResearch Triangle · $500K – $4Mvia Clay Thorp · board
How we know: a partner's Signal profile · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$40.6M disclosed across 6 rounds · 2012–2019
▶$3.3MraisedDec 2019 · 3 investors · PharmaceuticalsRule 506(b)
▶$3.3MraisedDec 2019 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- George LasezkayExecutive Officer, Director
- Charles A. DeignanExecutive Officer
- William D. HumphriesDirector
- Clay B. ThorpDirector
- Jeffrey L. EdwardsDirector
- Christy ShafferDirector
- Richard CroarkinDirector
- Offering amount
- $3.3M
- Amount sold
- $3.3M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$320KraisedOct 2016 · 2 investors · PharmaceuticalsRule 506(b)
▶$320KraisedOct 2016 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- William D. HumphriesDirector
- Gerald Cagle, Ph.D.Director
- Evgeny ZaytsevDirector
- Derek YoonDirector
- Christy L. Shaffer, Ph.D.Director
- Charles DeignanExecutive Officer
- Glenn NoronhaExecutive Officer
- Clay B. ThorpDirector
- Daniel H. WhiteExecutive Officer, Director
- Richard CroarkinDirector
- Offering amount
- $320K
- Amount sold
- $320K
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.4MraisedDec 2015 · 9 investors · Other TechnologyRule 506(b)
▶$14.4MraisedDec 2015 · 9 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Charlie DeignanExecutive Officer
- Clay ThorpDirector
- William HumphriesDirector
- Evgeny ZaytsevDirector
- Christy ShafferDirector
- Daniel WhiteExecutive Officer, Director, Promoter
- Gerald D. CagleDirector
- Offering amount
- $20M
- Amount sold
- $14.4M
- First sale
- Nov 2015
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$16.2MraisedSep 2014 · 31 investors · PharmaceuticalsRule 506(b)
▶$16.2MraisedSep 2014 · 31 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christy ShafferDirector, Promoter
- Clay ThorpDirector
- Daniel H. WhiteExecutive Officer, Director, Promoter
- Charles A. DeignanExecutive Officer
- Glenn NoronhaExecutive Officer
- Evgeny ZaytsevDirector
- William HumphriesDirector
- Mark PrausnitzDirector, Promoter
- Gerald D. CagleDirector
- Offering amount
- $20M
- Amount sold
- $16.2M
- Minimum investment
- $50K
- Finders' fees
- $118K
- Proceeds to insiders
- $550K
- First sale
- Aug 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$3MraisedMay 2014 · 13 investors · PharmaceuticalsRule 506(b)
▶$3MraisedMay 2014 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- William HumphriesDirector
- Jerry CagleDirector
- Clay ThorpDirector
- Mark PrausnitzDirector
- Charles A. DeignanExecutive Officer
- Glenn NoronhaExecutive Officer
- Daniel H. WhiteExecutive Officer, Director
- Christy ShafferDirector
- Offering amount
- $6M
- Amount sold
- $3M
- Proceeds to insiders
- $450K
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$3.2MraisedFeb 2012 · 7 investors · PharmaceuticalsRule 506(b)
▶$3.2MraisedFeb 2012 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christy ShafferDirector
- Clay ThorpDirector
- Daniel H. WhiteExecutive Officer
- Mark PrausnitzDirector
- Offering amount
- $4M
- Amount sold
- $3.2M
- Minimum investment
- $37.5K
- Proceeds to insiders
- $500K
- First sale
- Jan 2012
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Clearside Biomedical went on to found or lead other companies.
Related companies · 5
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Companies working in the same space as Clearside Biomedical.
In the news
Frequently asked questions
- What does Clearside Biomedical do?
- Clearside Biomedical is an intellectual property holding, investment, and commercialization company focused on its suprachoroidal space (SCS) ocular drug-delivery platform and microinjector technology. Following its emergence from Chapter 11 in 2026, it works to rehabilitate, use, and monetize its retained intellectual property.
- Who founded Clearside Biomedical?
- Clearside Biomedical was founded by Mark Prausnitz in 2011.
- Who are Clearside Biomedical's investors?
- Clearside Biomedical's investors include HEALTHCARE ROYALTY PARTNERS, Mountain Group Capital, Solasta Ventures, Hatteras, Hatteras Venture Partners.
- How much funding has Clearside Biomedical raised?
- Clearside Biomedical has disclosed $40.6M raised across 6 rounds.
- Where is Clearside Biomedical headquartered?
- Clearside Biomedical is headquartered in Alpharetta, US.